
    
      A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy
      and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation
      and rebound for a further 40 weeks open-label extension treatment period in subjects
      suffering from moderate to severe Restless Legs Syndrome.
    
  